These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30735682)

  • 1. Ophthalmic Immune-Related Adverse Events of Immunotherapy: A Single-Site Case Series.
    Kim JM; Materin MA; Sznol M; Kluger HM; Weiss S; Chow J; Stoessel K; Kombo N; Del Priore L; Pointdujour-Lim R
    Ophthalmology; 2019 Jul; 126(7):1058-1062. PubMed ID: 30735682
    [No Abstract]   [Full Text] [Related]  

  • 2. Widespread subacute cutaneous lupus erythematosus in a patient receiving checkpoint inhibitor immunotherapy with ipilimumab and nivolumab.
    Kosche C; Owen JL; Choi JN
    Dermatol Online J; 2019 Oct; 25(10):. PubMed ID: 31735010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Poliosis Following Checkpoint Inhibitor Treatment for Cutaneous Melanoma.
    Ediriwickrema LS; Liu CY; Kikkawa DO; Korn BS
    Ophthalmic Plast Reconstr Surg; 2019; 35(5):e121-e122. PubMed ID: 31373986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis.
    Abdelhafeez AAM; Shohdy KS; Ibrahim W
    Cancer Invest; 2020 Mar; 38(3):150-157. PubMed ID: 31977260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series.
    Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC
    J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK; Watson DE
    Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy-induced autoimmune hypophysitis.
    Valecha G; Pant M; Ibrahim U; Atallah JP
    J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Histoseminar on inflammatory bowel diseases (IBD): Case n
    Fléjou JF
    Ann Pathol; 2017 Aug; 37(4):298-301. PubMed ID: 28734677
    [No Abstract]   [Full Text] [Related]  

  • 9. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
    Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
    Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
    [No Abstract]   [Full Text] [Related]  

  • 10. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I; Malinzak M; Salama AKS
    J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-Onset Inflammatory Optic Nerve Sheath Mass and Perineuritis Following Cessation of Ipilimumab and Nivolumab Therapy.
    Kamboj A; Hwang CJ; McClelland CM; Maltry AC; Harrison AR; Mokhtarzadeh A
    Ophthalmic Plast Reconstr Surg; 2022 Jul-Aug 01; 38(4):e119-e122. PubMed ID: 35797675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of immunotherapy-induced immune-related adverse events.
    Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
    Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy.
    Irwin DE; Davis B; Bell JA; Galaznik A; Garcia-Ribas I
    J Comp Eff Res; 2019 Jan; 8(2):81-90. PubMed ID: 30547675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center.
    El Majzoub I; Qdaisat A; Thein KZ; Win MA; Han MM; Jacobson K; Chaftari PS; Prejean M; Reyes-Gibby C; Yeung SJ
    Ann Emerg Med; 2019 Jan; 73(1):79-87. PubMed ID: 29880440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory Neutropenia Secondary to Dual Immune Checkpoint Inhibitors That Required Second-Line Immunosuppression.
    Meti N; Petrogiannis-Haliotis T; Esfahani K
    J Oncol Pract; 2018 Aug; 14(8):514-516. PubMed ID: 30004823
    [No Abstract]   [Full Text] [Related]  

  • 16. Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.
    Smith MH; Bass AR
    Arthritis Care Res (Hoboken); 2019 Mar; 71(3):362-366. PubMed ID: 29125905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
    De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
    J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anorexia, vomiting and weight loss in a 22-year-old woman.
    Cheung VTF; Fryer E; Payne MJ; Brain O
    Gut; 2019 May; 68(5):803-927. PubMed ID: 30061188
    [No Abstract]   [Full Text] [Related]  

  • 19. Case 9-2020: A 64-Year-Old Man with Shortness of Breath, Cough, and Hypoxemia.
    Reynolds KL; Sullivan RJ; Fintelmann FJ; Mansour MK; England J
    N Engl J Med; 2020 Mar; 382(12):1150-1159. PubMed ID: 32187473
    [No Abstract]   [Full Text] [Related]  

  • 20. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
    J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.